Skip to main content

Quick Connect

Ramipril

Ramipril-API

Ramipril API

CAS Number: 87333-19-5

About Ramipril API

Therapeutic Category
Cardiovascular

API Technology
Synthetic

Dose Form
Oral Solids

Dr Reddy's Development Status
Available

Available Regulatory Filing
USDMF

Mechanism of Action

ACE inhibitors inhibit the actions of angiotensin converting enzyme (ACE), thereby lowering the production of angiotensin II and decreasing the breakdown of bradykinin. The decrease in angiotensin II results in relaxation of arteriole smooth muscle leading to a decrease in total peripheral resistance, reducing blood pressure as the blood is pumped through widened vessels. Its effect on bradykinin is responsible for the dry cough side effect. Ramipril, a prodrug or precursor drug, is converted to the active metabolite ramiprilat by carboxylesterase

Indication

ALTACE is an angiotensin converting enzyme (ACE) inhibitor indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It may be used alone or in combination with thiazide diuretics.

In patients 55 years or older at high risk of developing a major cardiovascular event, ALTACE is indicated to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. ALTACE is indicated in stable patients who have demonstrated clinical signs of congestive heart failure post-myocardial infarction

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Ramipril API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Ramipril API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.

Contact Us

OR
We are here to help, if you have any country specific requirements.

Related Resources

Tech Sheet - Dr. Reddy’s Ramipril API offerings

Tech Sheet - Dr. Reddy’s Ramipril API offerings

Ramipril is an angiotensin-converting enzyme (ACE) inhibitor indicated for treating hypertension to lower blood pressure. ACE inhibitors inhibit the angiotensin-converting enzyme (ACE) actions, thereby reducing the production of angiotensin II and decreasing the breakdown of bradykinin. The decrease in angiotensin II results in relaxation of arteriole smooth muscle leading to a reduction in total peripheral resistance, reducing blood pressure as the blood is pumped through widened vessels.

Ramipril works by lowering blood pressure and reducing the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. In addition, Ramipril, in combination with thiazide diuretics, is used to treat hypertension.

Dr. Reddy's is among the earliest generic API manufacturers globally to file the USDMF for Ramipril API. On October 4, 2000, the FDA approved the original dosage form, i.e., Altace® capsules, to reduce the risk of myocardial infarction, stroke, and cardiovascular diseases.

To know more about our API offerings, please read the technical sheet on Ramipril by filling the contact from below.

Read More Read More

Related APIs

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.

FAQs

High blood pressure, heart failure, and diabetic kidney disease.

Hypertension - 2.5 mg orally. Congestive Heart Failure - 2.5 mg orally twice a day.Cardiovascular Risk Reduction - 2.5 mg orally once a day for one week.

Blood tests to check how well your kidneys are working and the amount of potassium in your blood

We offer Crystalline Form

Meet with our product experts in one-on-one virtual sessions at https://api.drreddys.com/meet-api-experts or Write to us at api@drreddys.com.

Insights Delivered

Sign-up for our email service to get Market and Product insights and updates right to your digital doorstep

The categories of personal information collected in this form include name, company, and contact information etc. The personal information collected will be used for exploratory discussions on contract manufacturing, marketing and to perform research and analytics and others. For more information about the categories of personal information collected by Dr.Reddy's and the purposes for which Dr.Reddy's uses personal information, visit https://api.drreddys.com/privacy-policy.

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.